The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Author:

Guven Deniz Can1ORCID,Erul Enes2ORCID,Sahin Taha Koray2ORCID,Dizdar Omer1,Yalcin Suayib1,Sahin Ibrahim Halil3ORCID

Affiliation:

1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06100, Turkey

2. Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey

3. Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA

Abstract

Background: A systemic review of the survival benefit of immune checkpoint inhibitors (ICIs) in phase III hepatocellular carcinoma (HCC) trials was conducted. Methods: Meta-analyses were performed with the generic inverse-variance method with a fixed-effects model. Results: In 10 trials encompassing 6123 patients, ICI-based therapy (monotherapy/combination) improved overall survival (OS) compared with the control arm (hazard ratio [HR]: 0.77; 95% CI: 0.70–0.84; p < 0.001). The survival benefit was consistent across variable treatment lines, Eastern Cooperative Oncology Group performance status and AFP levels. While the OS benefit was more pronounced in hepatitis B-related HCC (HR: 0.70; 95% CI: 0.63–0.77; p < 0.001), OS was improved in hepatitis C-related (HR: 0.83; 95% CI: 0.71–0.98) and nonviral HCC (HR: 0.86; 95% CI: 0.77–0.97). Conclusion: ICI-based therapies should be the standard for all patients with advanced HCC.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3